article thumbnail

GreenLight and US NIH partner to develop Covid-19 vaccine for variants

Pharmaceutical Technology

The company will jointly design and analyse messenger ribonucleic acid (mRNA) Covid-19 vaccines in partnership with the NIH unit National Institute of Allergy and Infectious Diseases’ Vaccine Research Center (VRC). They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Vaccine 245
article thumbnail

Gilead’s Veklury receives WHO recommendation to treat severe Covid-19

Pharmaceutical Technology

These results are in line with those obtained from the placebo-controlled, double-blind ACTT-1 trial of the National Institute of Allergy and Infectious Diseases. A nucleotide analog, Veklury hinders viral replication in the cell by acting on the RNA polymerase of the SARS-CoV-2 virus.

Allergies 277
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Donidalorsen Shows Sustained HAE Attack Reduction According to New Trial Data

XTalks

Carlsbad, California-based Ionis Pharmaceuticals announced it will be sharing promising new trial data for its RNA-targeted prophylactic treatment donidalorsen for hereditary angioedema (HAE) at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI)/World Allergy Organization (WAO) Joint Congress in San Diego, California.

Trials 59
article thumbnail

Moderna’s Covid-19 shot gets Australian TGA provisional approval for kids

Pharmaceutical Technology

Moderna has received provisional registration from the Australian Therapeutic Goods Administration (TGA) for its messenger RNA (mRNA) Covid-19 vaccine, Spikevax, for kids aged six months to five years. The 25µg two-dose vaccine regimen is indicated for active immunisation for the prevention of Covid-19.

Vaccine 246
article thumbnail

Study identifies noncoding RNA involved in immune response and sepsis

Scienmag

A long noncoding RNA regulates the expression of inflammatory genes and has a surprising effect on vulnerability to septic shock in mice Credit: Apple Vollmers When the body’s immune response to an infection gets out of control, the result can be sepsis, a life-threatening condition in which an overwhelming inflammatory response can lead rapidly (..)

article thumbnail

HIV vaccines suffer setbacks but new approaches could turn the tide

Pharmaceutical Technology

Now, the HIV research community is setting its sights on vaccines that are in earlier stages of development, based on new approaches like messenger RNA (mRNA) -based vaccines or those using human cytomegalovirus (HCMV) vectors.

Vaccine 293
article thumbnail

Agents that target viral RNA could be the basis for next generation anti-viral drugs

Scienmag

A new approach to tackling viruses by targeting the ‘control centre’ in viral RNA could lead to broad spectrum anti-viral drugs and provide a first line of defence against future pandemics, according to new research at the University of Birmingham.

RNA 49